Vertex Pharmaceuticals Inc. diskutieren

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $438.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $457.00 to $462.00. They now have a "buy" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Piper Sandler from $450.00 to $456.00. They now have an "overweight" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $462.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at BMO Capital Markets from $480.00 to $500.00. They now have an "outperform" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $465.00 to $550.00. They now have a "buy" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Wells Fargo & Company from $540.00 to $555.00. They now have an "overweight" rating on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $545.00 price target on the stock.

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.

Vertex Pharmaceuticals is a biotech powerhouse that has caught my attention. Their recent FDA acceptance of the NDA for their vanza triple therapy for cystic fibrosis is a game-changer. This new treatment could be a life-changing breakthrough for patients. The priority review status is a testament to the potential of this therapy. Additionally, the positive analyst coverage from Redburn Atlantic, with a buy rating and a $545 target price, further solidifies my confidence in Vertex's future prospects. It's like they have the golden ticket in the biotech world, and I'm excited to see what other innovations they have up their sleeve. While no investment is without risk, Vertex's strong pipeline, track record, and promising developments make it an attractive option for growth-oriented investors like myself.